Marc Salzberg
Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study
Salzberg M, Thürlimann B, Hasler U, Delmore G, von Rohr A, Thurlimann A, Ruhstaller T, Stopatschinskaja S, von Moos R. Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study. Oncology 2007; 72:147-51.
Jan 1, 2007Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study
Jan 1, 2007Oncology 2007; 72:147-51
Salzberg Marc, Thürlimann Beat, Hasler Ursula, Delmore Geoffrey, von Rohr Albert, Thurlimann Annatina, Ruhstaller Thomas, Stopatschinskaja Shanna, von Moos Roger
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Jermann M, Bauer J, Rhyner K, Egli F, Morant R, Gillessen Sommer S, Jörger M, Cerny T, Salzberg M, Stahel R, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy and pharmacology 2006; 57:533-9.
Apr 1, 2006A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Apr 1, 2006Cancer chemotherapy and pharmacology 2006; 57:533-9
Jermann Monika, Bauer Jean A, Rhyner Kaspar, Egli Fritz, Morant Rudolf, Gillessen Sommer Silke, Jörger Markus, Cerny Thomas, Salzberg Marc, Stahel Rolf A, Pless Miklos
Current concepts of treatment strategies in advanced or recurrent ovarian cancer
Salzberg M, Thürlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, Senn H. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005; 68:293-8.
Jan 1, 2005Current concepts of treatment strategies in advanced or recurrent ovarian cancer
Jan 1, 2005Oncology 2005; 68:293-8
Salzberg Marc, Thürlimann Beat, Bonnefois Hervé, Fink Daniel, Rochlitz Christoph, von Moos Roger, Senn Hansjorg
An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing
Leuppi J, Salzberg M, Meyer L, Bucher S, Nief M, Brutsche M, Tamm M. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2003; 133:302-9.
May 31, 2003An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing
May 31, 2003Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2003; 133:302-9
Leuppi Jörg D, Salzberg Marc, Meyer L, Bucher S E, Nief M, Brutsche Martin, Tamm Michael